AstraZeneca in the UK resumes clinical trials of new crown vaccine

Science and Technology Daily, Beijing, September 14 (Reporter Liu Xia) According to a report by the American Physicist Organization Network on the 13th, AstraZeneca and Oxford University announced on the 12th local time that they have recovered after obtaining permission from the British regulatory agency.

According to a British Reuters report on September 10, the chief scientist of the World Health Organization Sumia Swaminathan said on the 10th that after a British subject had a "suspected serious adverse reaction" after being vaccinated with the AZD1222 vaccine, AstraZeneca The company suspended clinical trials of the vaccine

AstraZeneca's website reported on September 12 that the company proactively suspended its clinical trials of the new crown vaccine in many places around the world on the 6th, so that an independent international committee can review relevant safety data

The University of Oxford also confirmed the news of the resumption of clinical trials of the vaccine, and said: “18,000 people worldwide have received this vaccine in clinical trials.

AstraZeneca and the University of Oxford stated on the 12th that in order to protect the privacy of subjects, they will not disclose more information about subjects with diseases, but will update all trial investigators and participants in accordance with clinical trials and regulatory standards.

The AZD1222 vaccine is one of the nine new coronavirus vaccines currently in the late stage of phase III clinical trials

It is reported that the AZD1222 vaccine will start a phase III clinical trial in the United States on August 31.

Although the AZD1222 vaccine is still in clinical trials, relevant departments and companies in the European Union, Australia and many other places have announced an agreement with AstraZeneca to obtain the vaccine or its production license after the clinical trial is successful